Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCD-101 in Adults With Sickle Cell Disease
NCT02380079Phase 1Unknown
- Sponsor
- Invenux, LLC
- Start
- Feb 2015
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in sickle cell disease (SCD) comparing SCD-101 with Placebo (2 arms). Primary endpoint: Frequency and severity of adverse events at 18 weeks. Status: unknown.
02
Drugs
SCD-101
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02380079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02380079.